Posts by: David Melamed, PhD

David Melamed, PhD

David earned a PhD in Biological Sciences from Columbia University in New York, NY, where he studied how Drosophila ovarian adult stem cells respond to cell signaling pathway manipulations. This work helped to redefine the organizational principles underlying adult stem cell growth models. He is currently a Science Writer, as part of the BioNews Services writing team.

October 14, 2020October 14, 2020

Enrollment Underway in Melanoma Trial Testing Leukine Triple Combo

News

A Phase 2/3 clinical trial is again recruiting participants to continue investigating the immunomodulator Leukine (sargramostim) in combination with checkpoint inhibitors Yervoy (ipilimumab) and Opdivo (nivolumab) as an initial treatment ... Read more

May 26, 2020May 26, 2020

ONCOS-102 Plus Chemo Showing Sustained Benefit in Mesothelioma Trial

News

A combination of ONCOS-102 plus standard chemotherapy continues to extend the time without disease progression and appears to induce immune system activity in people with malignant pleural mesothelioma unable to ... Read more

April 21, 2020April 21, 2020

Bavencio Seen as Ineffective in Phase 3 Head and Neck Cancer Trial

News

A Phase 3 trial of Bavencio (avelumab) in people with squamous cell carcinoma of the head and neck (SCCHN) was ended early due to a lack of effectiveness seen in ... Read more

April 7, 2020April 7, 2020

Early Success in Phase 3 Trial of Sacituzumab Govitecan in Triple-Negative Breast Cancer

News

A Phase 3 clinical trial investigating Immunomedics‘ potential therapy sacituzumab govitecan is ending early because existing results have shown sufficient evidence that the treatment is effective in patients with triple-negative ... Read more

February 26, 2020March 23, 2020

First Patient Enrolled in Phase 1 Trial Investigating Galinpepimut-S and Opdivo for MPM

News

Investigators enrolled the first patient in a Phase 1 clinical trial to evaluate the effects of the cancer vaccine galinpepimut-S in combination with immune checkpoint inhibitor Opdivo (nivolumab) as a ... Read more

February 19, 2020February 19, 2020

Potential CAR T-cell Therapy Targeting ROR1 Seen to Clear Cancer in Leukemia Mouse Model

News

A potential new CAR T-cell therapy by Oncternal Therapeutics showed strong activity against leukemia in mice, completely eliminating cancer cells from major “tissue reservoirs” in four weeks and extending survival by ... Read more

February 10, 2020February 10, 2020

Geneos to Test GNOS-PV02 Cancer Vaccine in Triple Combo Trial for Advanced Liver Cancer

News

Geneos Therapeutics is gearing up to initiate a Phase 1/2 trial of a triple immunotherapy combination, including its patient-specific cancer vaccine GNOS-PV02, in people with advanced hepatocellular carcinoma (HCC), the ... Read more

January 27, 2020January 31, 2020

Cabometyx, Opdivo, Yervoy Triple Combo Shows Potential Benefits in Advanced HCC, Trial Data Show

News

A combination of Opdivo (nivolumab) and Cabometyx (cabozantinib), with or without Yervoy (ipilimumab), induces clinically meaningful responses in people with advanced hepatocellular carcinoma (HCC) — the most common type of ... Read more

January 23, 2020January 29, 2020

FDA to Review Tecentriq-Avastin Combo for Newly Diagnosed Advanced Liver Cancers

News

Genentech has submitted an application to the U.S. Food and Drug Administration to extend the use of Tecentriq (atezolizumab), in combination with Avastin (bevacizumab), for the treatment of people with ... Read more

January 22, 2020

First Patient Dosed in Phase 1/2 Trial Testing HB-201 Vaccine for HPV16+ Cancers, Hookipa Pharma Announces

News

The first patient has been dosed in a Phase 1/2 trial testing Hookipa Pharma‘s experimental cancer vaccine HB-201, alone or in combination with an immune checkpoint inhibitor, in people with ... Read more